Vicore Pharma to Participate in the Guggenheim Annual Healthcare Innovation Conference and the Stifel Healthcare Conference
STOCKHOLM, SE / ACCESS Newswire / November 2, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), a biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists, today announced that the company will participate in the following upcoming healthcare conferences:
Guggenheim 3rd Annual Healthcare Innovation Conference
- Location: InterContinental Boston, Boston
- Format: Fireside chat and 1×1 meetings
- Date and time: Monday, November 9, 2026, 8:00-8:25 AM ET
- Participant: Ahmed Mousa, Chief Executive Officer
- Webcast: Link
Stifel 2026 Healthcare Conference
- Location: Lotte New York Palace, New York
- Format: Presentation and 1×1 meetings
- Date and time: Thursday, November 12, 2026, 10:40-11:10 AM ET
- Participant: Ahmed Mousa, Chief Executive Officer
- Webcast: Link
For further information, please contact:
Hans Jeppsson, Chief Financial Officer, +46 (0)70 553 14 65, hans.jeppsson@vicorepharma.com
About Vicore Pharma Holding AB
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small-molecule angiotensin II type 2 receptor agonist, which received Orphan Drug and Fast Track designations from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com
SOURCE: Vicore Pharma Holding
View the original press release on ACCESS Newswire
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
This Once-Hot AI Stock Now Looks Deeply Undervalued
5 Stocks to Buy Trading at Big Discounts
Tech Stocks Sell Off as Intel, Amazon Earnings Spook Investors
2 Undervalued AI Stocks With Room to Run
United States